JIC
AVIR icon

Johnson Investment Counsel’s Atea Pharmaceuticals AVIR Stock Holding History

Johnson Investment Counsel’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$98.7K Hold
18,340
– – ﹤0.01% 798
2025
Q4 		$65.5K Hold
18,340
– – ﹤0.01% 782
2025
Q3 		$53.2K Buy
18,340
+3,000
+20% +$10.2K ﹤0.01% 817
2025
Q2 		$55.2K Buy
+15,340
New +$45.7K ﹤0.01% 808

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Johnson Investment Counsel's AVIR Position: Q1 2026 in Review

Johnson Investment Counsel held its Atea Pharmaceuticals (AVIR) position steady in Q1 2026 at 18,340 shares worth $98.7K. The position accounts for ﹤0.01% of the portfolio, ranked #798.

Johnson Investment Counsel first reported a position in AVIR in Q2 2025 and has held it in 4 quarters since. 127 funds tracked by Wall St. Rank hold AVIR as of Q1 2026.

  • Johnson Investment Counsel held 18,340 shares of Atea Pharmaceuticals worth $98.7K as of Q1 2026.
  • Johnson Investment Counsel left its Atea Pharmaceuticals share count unchanged in Q1 2026.
  • Atea Pharmaceuticals made up ﹤0.01% of Johnson Investment Counsel's portfolio in Q1 2026, its #798 holding.
  • Johnson Investment Counsel first reported a position in Atea Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • 127 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2026.

Based on Johnson Investment Counsel's 13F filing for Q1 2026, filed 4 May 2026.